A proposed settlement of $20 million has been reached in a class action lawsuit against VSL Pharmaceuticals, Inc. for allegedly misrepresenting the effectiveness of their probiotic product VSL#3.
Key takeaway
$20m proposed settlement in class action against VSL Pharmaceuticals for misleading probiotic claims.
- Step 1 · The triggerVSL Pharmaceuticals reaches a $20 million settlement in a class action lawsuit.
- Step 2 · Knock-onConsumers lose trust in VSL#3, leading to decreased sales for VSL Pharmaceuticals.
- Step 3 · Reaches youOther probiotic manufacturers gain market share as consumers shift their purchases away from VSL#3.
The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.
Source: PR Newswire
See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for your businessThis is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.